Pediatric Oncology Physician - MSK Kids

   

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe.

 

The Department of Pediatrics of Memorial Sloan Kettering Cancer Center (MSK) is recruiting a clinician-investigator and pediatric oncologist with research and clinical expertise in pediatric solid tumors.  The candidate will lead efforts in translating laboratory-based research into early phase clinical trials, and clinical care as part of the Rare Tumors Program and Pediatric Translational Medicine Service. 

The mission of the Rare Tumors Program is to improve the outcomes of children, adolescents, and young adults with rare pediatric solid tumors, including embryonal tumors of the hepatic and genitourinary systems as well as tumors of epithelial origin more commonly affecting adults.   The Program recognizes that pediatric patients with rare tumors have unique needs that are best managed by an integrated team of experts which bridges the bench and bedside.

The Pediatric Translational Medicine Service embodies the Department’s commitment to provide precision medicine to each patient – particularly those with rare tumors.  Using state-of-the art methods we lead the initiative to profile the genome of every patient’s tumor, generate preclinical models, perform additional testing to discover vulnerabilities and present cases in multidisciplinary tumor boards to ensure each patient has had all options explored, and can decide which treatment is best for them.  Investigator-initiated, consortium, and pharmaceutical sponsored early phase trials that bridge multiple histologies, are biomarker enriched, and feature molecularly targeted agents including small molecules, antibody-drug conjugates and various immunotherapies, are conducted through this service.

The Rare Tumors Program and Pediatric Translational Medicine Service are integrated with other collaborative clinical and research efforts throughout the institution including the Tow Center for Developmental Oncology, the Pediatric Cancer Predisposition Program, the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers, and the Early Drug Development Service in the Department of Medicine. 

As a member of the Rare Tumors Program and Pediatric Translational Medicine Service, you will have the responsibility for:

• Clinical activities including:
  • Primary responsibility of Program/Service patients, including regular outpatient pediatric oncology clinic
  • Periodic coverage of the inpatient pediatric oncology service, notably including all oncology diagnoses
  • Lumbar puncture and/or bone marrow procedures, only if required for Program/Service patient
• Translational research activities including:
  • Oversight of clinical and research tumor profiling efforts
  • Oversight of departmental biobanking and preclinical modeling efforts
  • Collaboration with basic science laboratories to inform early phase clinical research
  • Development of investigator initiated targeted and immune-therapy based clinical trials for pediatric solid tumors
• Academic activities including:
  • Translational research and publications
  • Securing of independent grant funding
  • Co-leading departmental molecular tumor boards
  • Education of fellows, residents and staff

Key Requirements:

• Applicants must possess a full unrestricted license to practice medicine in the State of New York (or must be licensed in another jurisdiction and be eligible for licensure in New York and New Jersey).
• They must possess a Doctor of Medicine (MD), Osteopathy (DO) or equivalent.
• Board-certified in Pediatrics and or Board-eligible in Pediatric Hematology/Oncology
• Eligible for appointment ranging from Assistant to Full Professor.

Candidate Characteristics:

• Ability to anticipate cancer behavior and approach cancer heterogeneity in innovative ways
• Ability to work in a team environment of care providers, researchers, administration and data managers
• Experience in translational research
• Experience in design and implementation of clinical trials

Submit C.V., letter of interest, and references in your application submission to:

           

Julia Glade Bender, MD

c/o: Nydia Toribio

[email protected]

Pay Range: $192,000 - $376,750

Helpful links:  

• MSK Compensation Philosophy
• Review Our Great Benefits Offerings

Physician compensation is based on multiple variables. This range represents annual salary only and does not include supplemental performance-based pay or any one-time payments that eligible candidates may be offered at the time of hire.

 

Pay Range: $0.00 - $10,000,000.00

 

FSLA Status: Exempt

 

Closing:

At MSK, we believe in fair, competitive pay that reflects your job, experience, and skills.

MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision.  

Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.